A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00168441

Enrollment

117

Registered

2005-09-15

Start date

2004-06-30

Completion date

2005-06-30

Last updated

2011-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postherpetic Neuralgia

Brief summary

4-month study including a 30-day baseline phase

Interventions

DRUGBotulinum Toxin Type A

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.

Exclusion criteria

* Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.

Design outcomes

Primary

Measure	Time frame
Pain score	—

Secondary

Measure	Time frame
Various Quality of Life questionnaires	—
Reduction in area of pain/allodynia	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026